By Associate Professor Hao-Wen Sim

Journal articles

Satgunaseelan L; Xian E; Madani D; Gamage KK; Hallal SM; Gorolay V; Sim HW; Mason S; Buckland ME; Shivalingam B; Alexander KL, 2026, 'Impact of an evolving classification system on diffuse glioma repositories: experience from the Sydney brain tumour bank', Journal of Neuro Oncology, 177, pp. 6, http://dx.doi.org/10.1007/s11060-026-05470-1

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim HW; Krasovitsky M; Kong BY; Miller S; Buckland ME; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Turner C; Back MF; Pavlakis N; Wei JQ; Hudson A; Chan DL; Wheeler HR; Lee A, 2025, 'Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey', Neuro Oncology Practice, 12, pp. 787 - 796, http://dx.doi.org/10.1093/nop/npaf045

Shekar S; Crumbaker M; Joshua A; Yam A; Stricker P; Yuen C; Ende D; Namdarian B; Thompson J; Kooner R; O'Neill G; Mo J; Sim HW; Hruby G; Kasraei F; Ho A; De Leon J, 2025, 'Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience', Bjui Compass, 6, http://dx.doi.org/10.1002/bco2.70055

Lamb LS; Sim HW; Ramus SJ; McCormack AI, 2025, 'Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology', Molecular and Cellular Endocrinology, 607, http://dx.doi.org/10.1016/j.mce.2025.112598

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Chambers CR; Watakul S; Schofield P; Howell AE; Zhu J; Tran AMH; Kuepper N; Reed DA; Murphy KJ; Channon LM; Pereira BA; Tyma VM; Lee V; Trpceski M; Henry J; Melenec P; Abdulkhalek L; Nobis M; Metcalf XL; Ritchie S; Cadell A; Stoehr J; Magenau A; Chacon-Fajardo D; Chitty JL; O’Connell S; Zaratzian A; Tayao M; Silva AD; Lyons RJ; Goldstein LD; Dale A; Rookyard A; Connolly A; Crossett B; Tran YTH; Kaltzis P; Vennin C; Dinevska M; Croucher DR; Samra J; Mittal A; Weatheritt RJ; Philp A; Monte-Nieto GD; Zhang L; Enriquez RF; Cox TR; Shi YCC; Pinese M; Waddell N; Sim HW; Chtanova T; Wang Y; Joshua AM; Chantrill L; Jeffry Evans TR; Gill AJ; Morton JP; Pajic M; Christ D; Herzog H; Timpson P; Herrmann D, 2025, 'Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis', Science Advances, 11, http://dx.doi.org/10.1126/sciadv.adq4416

Klingberg D; Bae S; Zhou DDX; Sim HW; Cai R; Anazodo A; Grimison P; Lewis C; Lee YC, 2025, 'Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma', Asia Pacific Journal of Clinical Oncology, 21, pp. 87 - 94, http://dx.doi.org/10.1111/ajco.13998

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, http://dx.doi.org/10.1136/BMJOPEN-2024-087922

Pham JP; Kondo M; Hurwitz J; Cosman R; Goldinger SM; Dummer R; Sim HW; Joshua AM, 2025, 'Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: A systematic review and meta-analysis', Ejc Skin Cancer, 3, http://dx.doi.org/10.1016/j.ejcskn.2025.100756

Shekar S; Hall A; Pham J; Crumbaker M; Liu J; Talmor B; Sim HW; Joshua AM, 2025, 'Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials', Endocrine Oncology, 5, http://dx.doi.org/10.1530/EO-25-0027

Bridgewater JA; Gardini AC; Wilmink H; Mercade TM; Sim H-W; Verslype C; Roderburg C; Touchefeu Y; McDermott RS; Kordes M; Lee C-K; Vogel A; Kzhdryan HGK; Vidra RA; Rumpold H; Sullivan A; Gharbi H; Minguez VM; Robert R; Rimassa L, 2025, '262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study', Annals of Oncology, 36, pp. S103 - S103, http://dx.doi.org/10.1016/j.annonc.2025.05.277

Rimassa L; Sim H-W; Hong JY; Lee C-K; Kim K-P; Eastgate M; Dean A; McLachlan S-A; Oh D-Y; Price TJ; Gharbi H; Robert R; Sullivan A; Malka D; Vogel A; Mercade TM, 2025, '280P Efficacy and safety of ivosidenib in Australian and South Korean patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study', Annals of Oncology, 36, pp. S1850 - S1851, http://dx.doi.org/10.1016/j.annonc.2025.10.107

Pitiyarachchi O; Lee CK; Sim H-W; Oconnell R; Lanceley A; Lobbedez FJ; Hilpert F; Pignata S; Berton-Rigaud D; Kaminsky-Forrett M-C; Okamoto A; Yoshida Y; Lindemann K; Oza AM; Berek JS; Ledermann JA; Friedlander ML, 2025, '604MO Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study', Annals of Oncology, 36, pp. S1941 - S1942, http://dx.doi.org/10.1016/j.annonc.2025.10.1041

Humphries TG; Roberts SK; Sim H-W; Kim YJ; Chon HJ; Heo J; Cohen H; Cioffi M; Barnett M; Maurer MA; Andelkovic V, 2025, 'A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps4218

Hallal SM; Tuzesi A; Vijayan A; Shivalingam B; Buckland ME; Gorolay V; Sim H; Satgunaseelan L; Vafaee F; Alexander KL, 2025, 'MACHINE LEARNING MODELS DETECT MULTIANALYTE BLOOD 'FINGERPRINTS FOR ACCURATE GLIOBLASTOMA SURVEILLANCE', NEURO-ONCOLOGY, 27, http://dx.doi.org/10.1093/neuonc/noaf193.226

Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V, 2024, 'Chemotherapy and radiotherapy for advanced pancreatic cancer', Cochrane Database of Systematic Reviews, 2024, http://dx.doi.org/10.1002/14651858.CD011044.pub3

Kornfeld B; Taha A; Kyang L; Sim HW; Dewhurst S; McCloy R; Chin V; Earls P; Parker A; Leavers B; Forstner D; Floros P; Crawford J; Gallagher R, 2024, 'Oncological outcomes post transoral robotic surgery (TORS) for HPV-associated oropharyngeal squamous cell carcinoma, a single-centre retrospective Australian study', Journal of Robotic Surgery, 18, http://dx.doi.org/10.1007/s11701-024-01910-0

Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503

Hallal SM; Sida LA; Tűzesi CÁ; Shivalingam B; Sim HW; Buckland ME; Satgunaseelan L; Alexander KL, 2024, 'Size matters: Biomolecular compositions of small and large extracellular vesicles in the urine of glioblastoma patients', Journal of Extracellular Biology, 3, http://dx.doi.org/10.1002/jex2.70021

Pereira BA; Ritchie S; Chambers CR; Gordon KA; Magenau A; Murphy KJ; Nobis M; Tyma VM; Liew YF; Lucas MC; Naeini MM; Barkauskas DS; Chacon-Fajardo D; Howell AE; Parker AL; Warren SC; Reed DA; Lee V; Metcalf XL; Lee YK; O'Regan LP; Zhu J; Trpceski M; Fontaine ARM; Stoehr J; Rouet R; Lin X; Chitty JL; Porazinski S; Wu SZ; Filipe EC; Cadell AL; Holliday H; Yang J; Papanicolaou M; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Vennin C; Yin J; Dew AB; McMillan PJ; Goldstein LD; Deveson IW; Croucher DR; Samuel MS; Sim HW; Batten M; Chantrill L; Grimmond SM; Gill AJ; Samra J; Jeffry Evans TR; Sasaki T; Phan TG; Swarbrick A; Sansom OJ; Morton JP; Pajic M; Parker BL; Herrmann D; Cox TR; Timpson P, 2024, 'Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response', Science Advances, 10, http://dx.doi.org/10.1126/sciadv.adl1197

Mason S; Chung S; Perez San Juan B; McCool C; Day B; Zaccaron Milioli H; Dear RF-G; Sim H-W; Holst J; Chaffer CL, 2024, 'Targeting androgen receptor signaling in glioblastoma: A novel biomarker and therapeutic approach.', Journal of Clinical Oncology, 42, pp. e14016 - e14016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14016

Satgunaseelan L; Lee M; Iannuzzi S; Hallal S; Deang K; Stanceski K; Wei H; Mason S; Shivalingam B; Sim HW; Buckland ME; Alexander KL, 2024, '‘The Reports of My Death Are Greatly Exaggerated’—Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma', Cancers, 16, http://dx.doi.org/10.3390/cancers16101906

Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME, 2024, 'Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play', Pathology, 56, pp. 158 - 169, http://dx.doi.org/10.1016/j.pathol.2023.11.003

Pham JP; Rodrigues A; Goldinger SM; Sim H-W; Liu JJ, 2024, 'Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14978

Sim H-W; McLachlan S-A; Dean A; Price TJ; Eastgate M; Rimassa L; Mercade TM; Malka D; Gharbi H; Robert R; Sullivan A; Vogel A, 2024, 'Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study', ANNALS OF ONCOLOGY, 35, pp. S1463 - S1463, http://dx.doi.org/10.1016/j.annonc.2024.10.171

Rimassa L; Bridgewater JA; Gardini AC; Wilmink H; Sim H-W; De Vos-Geelen J; Mercade TM; Malka D; Gharbi H; Robert R; Sullivan A; Vogel A, 2024, 'Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study', ANNALS OF ONCOLOGY, 35, pp. S236 - S236, http://dx.doi.org/10.1016/j.annonc.2024.08.069

Rimassa L; Bridgewater JA; Casadei-Gardini A; Wilmink H; Sim H-W; de Vos-Geelen J; Mercade TM; Malka D; Gharbi H; Robert R; Sullivan A; Vogel A, 2024, 'Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study', ANNALS OF ONCOLOGY, 35, pp. S1457 - S1457, http://dx.doi.org/10.1016/j.annonc.2024.10.159

Jiang DM; Parshad S; Zhan L; Sim HW; Siu LL; Liu G; Shapiro JD; Price TJ; Jonker DJ; Karapetis CS; Strickland AH; Zhang W; Jeffery M; Tu D; Ng S; Sabesan S; Shannon J; Townsend A; O'Callaghan CJ; Chen EX, 2023, 'Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer', Clinical Colorectal Cancer, 22, pp. 457 - 463, http://dx.doi.org/10.1016/j.clcc.2023.08.006

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Mason S; Chung S; Juan BPS; Sim H-W; Dear R; Day B; Holst J; Chaffer C, 2023, 'STEM-03. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA', Neuro-Oncology, 25, pp. v33 - v33, http://dx.doi.org/10.1093/neuonc/noad179.0130

Agar MR; Nowak AK; Hovey EJ; Barnes EH; Simes J; Vardy JL; Wheeler HR; Kong BY; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim HW; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh ES, 2023, 'Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study', BMJ Supportive and Palliative Care, 13, pp. 354 - 362, http://dx.doi.org/10.1136/spcare-2022-004119

Pham JP; On L; Ardolino L; Hurwitz J; Salaun H; Sim HW; Joshua AM, 2023, 'Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis', Melanoma Research, 33, pp. 316 - 325, http://dx.doi.org/10.1097/CMR.0000000000000900

Sim HW; Lorrey S; Khasraw M, 2023, 'Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas', Current Neurology and Neuroscience Reports, 23, pp. 263 - 276, http://dx.doi.org/10.1007/s11910-023-01268-0

Gan HK; Day BW; Harrup R; Johns TG; Lwin Z; Scott AM; Sim HW; Koh ES, 2023, 'Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future', Current Oncology Reports, 25, pp. 589 - 598, http://dx.doi.org/10.1007/s11912-023-01394-5

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Chan WY; Sim HW; Abdi Haryono M; Yip D; Chin V, 2023, 'Immune checkpoint inhibitors for advanced pancreatic cancer', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD014523

Lim J; Akbar Ali S; Prawira A; Sim HW, 2023, 'Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience', Internal Medicine Journal, 53, pp. 242 - 249, http://dx.doi.org/10.1111/imj.15561

Trinder SM; McKay C; Power P; Topp M; Chan B; Valvi S; McCowage G; Govender D; Kirby M; Ziegler DS; Manoharan N; Hassall T; Kellie S; Heath J; Alvaro F; Wood P; Laughton S; Tsui K; Dodgshun A; Eisenstat DD; Endersby R; Luen SJ; Koh ES; Sim HW; Kong B; Gottardo NG; Whittle JR; Khuong-Quang DA; Hansford JR, 2023, 'BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1154246

Pham JP; Hurwitz J; Cosman R; Goldinger SM; Sim HW; Dummer R; Joshua AM, 2023, 'Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis', ANNALS OF ONCOLOGY, 34, pp. S677 - S677, http://dx.doi.org/10.1016/j.annonc.2023.09.2261

Halkett GKB; Breen LJ; Berg M; Sampson R; Sim HW; Gan HK; Kong BY; Nowak AK; Day BW; Harrup R; James M; Saran F; Mcfarlane B; Tse C; Koh ES, 2022, 'Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers', Current Oncology, 29, pp. 9928 - 9955, http://dx.doi.org/10.3390/curroncol29120781

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Krasovitsky M; Buckland M; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikat W; Sim H-W; Kong B; Lwin Z; Turner C; Back M; Miller S; Lee A; Wheeler H, 2022, 'CSIG-13. CLINICAL IMPACT OF CDKN2A/B DELETIONS IN IDH-MUTANT ASTROCYTOMAS', Neuro-Oncology, 24, pp. vii41 - vii41, http://dx.doi.org/10.1093/neuonc/noac209.162

Sim H-W; Lwin Z; Barnes E; McDonald K; Yip S; Verhaak R; Heimberger A; Hall M; Wong M; Jennens R; Ashley D; Rosenthal M; Hovey E; Ellingson B; Tognela A; Gan H; Back M; Koh E-S; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson M; Kong B; Simes J; Khasraw M, 2022, 'CTIM-24. NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA', Neuro-Oncology, 24, pp. vii65 - vii65, http://dx.doi.org/10.1093/neuonc/noac209.256

Sim H-W; Lwin Z; Barnes E; McDonald K; Koh E-S; Rosenthal M; Foote M; Back M; Wheeler H; Buckland M; Walsh K; Fisher L; Leonard R; Hall M; Ashley D; Yip S; Simes J; Sulman E; Khasraw M, 2022, 'CTNI-42. GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA', Neuro-Oncology, 24, pp. vii81 - vii81, http://dx.doi.org/10.1093/neuonc/noac209.307

Doherty MK; Tam VC; McNamara MG; Jang R; Hedley D; Chen E; Dhani N; Tang P; Sim HW; O’Kane GM; DeLuca S; Wang L; Pedutem T; Knox JJ, 2022, 'Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer', British Journal of Cancer, 127, pp. 1473 - 1478, http://dx.doi.org/10.1038/s41416-022-01903-6

Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C, 2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058107

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia Pacific Journal of Clinical Oncology, 18, pp. 259 - 266, http://dx.doi.org/10.1111/ajco.13606

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Sim HW; Galanis E; Khasraw M, 2022, 'PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities', Cancers, 14, http://dx.doi.org/10.3390/cancers14041003

Malone ER; Sim HW; Stundzia A; Pierre S; Metser U; O’Malley M; Sacher AG; Sridhar SS; Hansen AR, 2022, 'Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma', Canadian Urological Association Journal, 16, http://dx.doi.org/10.5489/CUAJ.7467

Matsuyama M; Sachchithananthan M; Leonard R; Besser M; Nowak AK; Truran D; Vajdic CM; Zalcberg JR; Gan HK; Gedye C; Varikatt W; Koh ES; Kichenadasse G; Sim HW; Gottardo NG; Spyridopoulos D; Jeffree RL, 2022, 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro Oncology Practice, 9, pp. 68 - 78, http://dx.doi.org/10.1093/nop/npab055

Back to profile page